Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Journal Article

    Fury, M. G.; Krug, L. M.; Azzoli, C. G.; Sharma, S.; Kemeny, N.; Wu, N.; Kris, M. G.; Rizvi, N. A.
    Cancer Chemotherapy and Pharmacology (2006)

    Fulltext@MSK | Save
  • A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer
    Meeting Abstract

    Yee, L.; Lynch, T.; Villalona-Calero, M.; Rizvi, N.; Gabrail, N.; Sandler, A.; Cropp, G.; Palmer, G.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC
    Meeting Abstract

    Rizvi, N.; Pao, W.; Miller, V.; Rusch, V.; Heelan, R.; Ladanyi, M.; Ginex, P.; Tyson, L.; Zakowski, M.; Kris, M.
    Lung Cancer (2005)

    Fulltext@MSK | Save
  • Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC
    Meeting Abstract

    Ranson, M.; Bodkin, D.; Govindan, R.; Sleckman, B.; Rizvi, N.; Capo, A.; Germonpre, R.; Dimery, I.; Webster, A.; Natale, R.
    EJC Supplements (2005)

    Fulltext@MSK | Save
  • A comparison of the antitumour efficacy of ZD6474 and gefitinib (IresSa (TM)) in patients with NSCLC: Results of a randomized, double-blind phase II study
    Meeting Abstract

    Natale, R.; Bodkin, D.; Govindan, R.; Sleckman, B.; Rizvi, N.; Capo, A.; Germonpre, P.; Dimery, I.; Webster, A.; Ranson, M.
    Lung Cancer (2005)

    Fulltext@MSK | Save
  • Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Milton, D. T.; Kris, M. G.; Azzoli, C. G.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung
    Meeting Abstract

    Hussain, S.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Pao, W.; Riely, G.; Rizvi, N.; Gomez, J. E.; Miller, V.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor
    Meeting Abstract

    Fury, M. G.; Kris, M.; Solit, D.; Pfister, D. G.; Azzoli, C. G.; Henry, R.; Su, Y. B.; Rizvi, N.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Measurements of total DNA and methylated tumor suppressor genes in the plasma of patients with metastatic non-small cell lung cancer (NSCLC) before, and after chemotherapy, as potential biomarkers for response to treatment
    Meeting Abstract

    Azzoli, C. G.; Park, S.; Gomez, J.; Krug, L.; Miller, V.; Rizvi, N.; Ben-Porat, L.; Danenberg, K.; Danenberg, P.; Kris, M.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
    Journal Article

    Marshall, J. L.; Kindler, H.; Deeken, J.; Bhargava, P.; Vogelzang, N. J.; Rizvi, N.; Luhtala, T.; Boylan, S.; Dordal, M.; Robertson, P.; more...
    Investigational New Drugs (2005)

    Fulltext@MSK | Save